Mendly

About the offering

DNA Chat Corporation is building Mendly Care, a telemedicine platform that integrates AI symptom triage, full-genome sequencing, and encrypted DNA storage so that a patient's genetic data can be accessed and interpreted in real time during any doctor's visit. The company aims to replace traditional telemedicine with "DNA-First Virtual Care," where every appointment is genomically informed, turning a one-time $400 genome sequencing into a lifelong medical asset.The ProblemEvery year, more than 1 million Americans are seriously impaired or lose their lives due to misdiagnosis or adverse drug reactions. For rare genetic health conditions, Americans spend an average of six years and $116,500 before receiving the correct diagnosis. While roughly 5,000 rare genetic conditions collectively affect 30 million Americans, the majority have available genetic tests—but there are over 70,000 tests with 10 new ones added daily, making it nearly impossible for clinicians to identify the right one at the right time. Most genetic testing companies use genotyping that analyzes only a few known variants rather than the full genome, missing thousands of useful insights. Labs that do perform whole-genome sequencing typically label results as "research use only," making them clinically unusable. Meanwhile, eight of the ten leading causes of death in the US are strongly influenced by genetic factors, yet genomic data is almost never integrated into routine care.The SolutionMendly enables patients to sequence their entire genome once—even while healthy—at a cost of $400 (down from ~$10,000 a decade ago). The encrypted genome is stored securely with decryption keys held only on the patient's mobile app (Mendly GenVault, available on iOS and Android). When symptoms appear, Mendly's AI triage system instantly analyzes relevant regions of the patient's genome and generates real-time insights, which are reviewed by a certified genetic counselor or genetics expert and forwarded to the attending physician. The process narrows differential diagnosis from days to minutes. The platform also checks each individual's DNA for variants known to trigger adverse drug reactions, ensuring treatment safety. The patient experience mirrors traditional telemedicine except for one major improvement: speed—what once took a week or more for genetic test completion now takes minutes.Core TechnologyThe foundation is DNA Hyper-Sharding, a patent-pending privacy-preserving genomic storage technology. Each genome is divided into thousands of encrypted shards stored redundantly across multiple servers. Only the patient's mobile app holds decryption keys, and when a genetic test is needed, the app grants temporary, limited-scope access to only the relevant DNA regions. A DNA test can run in under two minutes, yet even a server breach would reveal nothing useful. The company claims HIPAA-grade privacy and post-quantum-resilient security. Additionally, an autonomous feedback system follows up with patients months after symptom reporting to ask whether a diagnosis was confirmed, creating a privacy-safe feedback loop that continuously improves accuracy and builds what the company describes as the world's first self-learning genomic intelligence.Business ModelMendly is designed to replace traditional telemedicine services with a similar billing structure, minimizing friction for employers, insurers, and individuals transitioning to DNA-first care. The primary go-to-market targets self-insured companies through health insurance and employee benefits brokers. The company claims an 8-30x cost advantage for self-insured employers: for a 1,000-employee company where 30% are married with one child, it would be roughly 11 times cheaper to fund DNA sequencing for all family members than to bear avoidable medical costs from approximately 60 cases of rare genetic diseases. Per-person savings are estimated at $200-$500 per year. The company has a gentleman's agreement with one broker to introduce Mendly to corporate clients after beta testing. Initial market opportunity is estimated at approximately $161M per year (under 1M customers), with plans to expand to traditional health insurer partnerships by 2029.Traction and Current StatusThe company has built its core technology infrastructure: the DNA Hyper-Sharding encryption is patent-pending with the USPTO, the GenVault App is fully developed for iOS and Android, and the live website accepts beta testers connected to telemedicine infrastructure. Mendly has signed a contract with a CLIA-certified laboratory for diagnostic-grade sequencing under US compliance and another contract with a white-label telemedicine provider licensed nationwide, enabling operation across all 50 states. The company is pre-revenue and pre-beta-launch. DNA Chat Corporation was built on prior research and software assets from Genomica Labs (now a wholly owned subsidiary), with all previous development costs and liabilities excluded from the new entity—described as providing a "clean financial slate" for investors.Go-to-Market TimelineThe rollout begins with direct-to-consumer beta testing, followed by national expansion through insurance and benefits brokers. By 2027, in-house sequencing capacity and a dedicated doctor network are planned to support large-scale operations. By 2029, formal reimbursement partnerships with health insurers are expected, enabling exponential growth as whole-genome sequencing becomes covered as part of standard care.TeamFounder and CEO Thiago Conrado holds a Master's and PhD in Genetics, was a Research Manager at DuPont-Pioneer, had a successful exit at his last startup, and brings 20 years of accumulated experience in genetics and blockchain. Co-Founder and Lead Developer Jack Langberg managed over $100M in crypto staking and holds degrees in Computer Science and Mathematics from NYU. Strategic Advisor Glenn Langberg is a C-level executive currently serving as CSO at Contract Pharmacal Corp and CEO of GRL Capital Companies, with clients including CVS, Walgreens, Cardinal Health, Sanofi, Bayer, and Kenvue.

FAQ